Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + paclitaxel + ifosfamide + cisplatin
- Development stage
- Unknown
- Lead developer
- Centre Léon Bérard
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
TIP-Centre Leon Berard-penile carcinoma refers to a combination chemotherapy and targeted therapy regimen being evaluated in a randomized Phase II clinical trial for the treatment of metastatic penile squamous cell carcinoma. The regimen consists of cetuximab, a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), combined with the TIP chemotherapy backbone. The TIP components include paclitaxel (a microtubule stabilizer), ifosfamide (an alkylating agent), and cisplatin (a platinum-based DNA cross-linking agent). This therapeutic approach, sponsored by the Centre Leon Berard in Lyon, France, aims to enhance the cytotoxic activity of standard cisplatin-based chemotherapy by inhibiting EGFR signaling, which is frequently overexpressed in penile cancer and associated with poor prognosis. The trial compares the efficacy and safety of this four-drug combination against the TIP regimen alone.
- Other names
- Cetuximab plus TIPCetuximab + TIP
02
Targets
Beyond the preview
Go deeper on cetuximab + paclitaxel + ifosfamide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + paclitaxel + ifosfamide + cisplatin.